Bios Fund III

Opus Genetics is a patient-first, science-driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, that focuses on developing microbiome-based therapeutics for skin diseases. Established in 2014, the company utilizes extensive scientific knowledge of the skin microbiome to create innovative treatments for various adverse skin conditions. Its technology platform is built around a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis, developed in collaboration with researchers from Yale University and the Jackson Laboratory. Azitra aims to address unmet medical needs in dermatology through its novel product offerings.

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics that target Glycogen Synthase Kinase-3ß (GSK-3ß) for Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, inflammatory conditions, and cancer. It develops compounds for combination use in high impact carcinomas, including glioblastoma, ovarian, breast, and pancreatic cancers. Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company was incorporated in 2015 and is based in Fort Worth, Texas with an additional office in Dublin, Ireland.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, that focuses on developing microbiome-based therapeutics for skin diseases. Established in 2014, the company utilizes extensive scientific knowledge of the skin microbiome to create innovative treatments for various adverse skin conditions. Its technology platform is built around a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis, developed in collaboration with researchers from Yale University and the Jackson Laboratory. Azitra aims to address unmet medical needs in dermatology through its novel product offerings.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Lung Therapeutics, Inc. is a pharmaceutical company based in Austin, Texas, that focuses on developing treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. The company's lead product, LTI-01, is an injectable fibrinolytic drug designed to remove fibrinous scar tissue around the lungs, thereby facilitating fluid drainage and minimizing complications. This product specifically addresses loculated pleural effusion, a severe complication of pneumonia characterized by fluid accumulation and scar tissue that obstructs drainage. Lung Therapeutics is also developing LTI-02, aimed at treating acute lung injury, and LTI-03, for idiopathic pulmonary fibrosis. Founded in 2012, the company seeks to enhance clinical pathways for patients suffering from these debilitating lung conditions.

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics that target Glycogen Synthase Kinase-3ß (GSK-3ß) for Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, inflammatory conditions, and cancer. It develops compounds for combination use in high impact carcinomas, including glioblastoma, ovarian, breast, and pancreatic cancers. Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company was incorporated in 2015 and is based in Fort Worth, Texas with an additional office in Dublin, Ireland.

Incysus Therapeutics is a operator of a biotechnology company intended to develop immune-based therapies for the treatment of cancer. The company's services focus on utilizing genetically modified gamma-delta T cells across a Drug Resistance Immunotherapy (DRI) platform that addresses the challenges faced while targeting cold, low mutation cancers, enabling the targeting of malignant cells and potentially more effective treatments for patients with difficult-to-treat solid tumor cancers.

Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, that focuses on developing microbiome-based therapeutics for skin diseases. Established in 2014, the company utilizes extensive scientific knowledge of the skin microbiome to create innovative treatments for various adverse skin conditions. Its technology platform is built around a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis, developed in collaboration with researchers from Yale University and the Jackson Laboratory. Azitra aims to address unmet medical needs in dermatology through its novel product offerings.

Lung Therapeutics, Inc. is a pharmaceutical company based in Austin, Texas, that focuses on developing treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. The company's lead product, LTI-01, is an injectable fibrinolytic drug designed to remove fibrinous scar tissue around the lungs, thereby facilitating fluid drainage and minimizing complications. This product specifically addresses loculated pleural effusion, a severe complication of pneumonia characterized by fluid accumulation and scar tissue that obstructs drainage. Lung Therapeutics is also developing LTI-02, aimed at treating acute lung injury, and LTI-03, for idiopathic pulmonary fibrosis. Founded in 2012, the company seeks to enhance clinical pathways for patients suffering from these debilitating lung conditions.

Lantern Pharma Inc. is a clinical-stage biotechnology company based in Dallas, Texas, specializing in the development of precision oncology therapeutics. The company utilizes artificial intelligence, genomics, and machine learning to create new classes of cancer drugs with innovative mechanisms of action. Its lead drug candidate, LP-100, is currently undergoing phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer. Lantern is also developing LP-300 as a combination therapy for female non-smokers with non-small cell lung cancer adenocarcinoma. Additionally, the company is advancing LP-184, an alkylating agent targeting cancer cells that express specific biomarkers. Lantern Pharma aims to improve the efficiency of oncology drug development by rescuing abandoned cancer drugs and using its proprietary RADR platform to enhance patient stratification and elucidate mechanisms of action, ultimately accelerating the development of personalized cancer therapies.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, that focuses on developing microbiome-based therapeutics for skin diseases. Established in 2014, the company utilizes extensive scientific knowledge of the skin microbiome to create innovative treatments for various adverse skin conditions. Its technology platform is built around a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis, developed in collaboration with researchers from Yale University and the Jackson Laboratory. Azitra aims to address unmet medical needs in dermatology through its novel product offerings.

410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.